why choose us

First received: November 23, 2023

Clinical Trial: EMPagliflozin After Aortic Valve Replacement

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Aortic Valve Stenosis

Study Type: INTERVENTIONAL


Official Title: EMPagliflozin After Aortic Valve Replacement - The EMPAVR Study - A Randomized Clinical Trial

Brief Summary: The study is a randomized, placebo-controlled, and double-blinded trial in patients with aortic stenosis (AS) undergoing aortic valve replacement (AVR). After AVR, patients will be randomized 1:1 to empagliflozin (SGLT2i) or placebo to investigate whether empagliflozin is superior to placebo in reducing left ventricular mass and improve symptoms to 6 months.

Read more